Home Cart Sign in  
Chemical Structure| 287953-38-2 Chemical Structure| 287953-38-2

Structure of 287953-38-2

Chemical Structure| 287953-38-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 287953-38-2 ]

CAS No. :287953-38-2
Formula : C11H22N2O4S
M.W : 278.37
SMILES Code : O=C(OC(C)(C)C)NC1CCN(S(=O)(C)=O)CC1
MDL No. :MFCD11852586
InChI Key :BVSNHVUSSUREGZ-UHFFFAOYSA-N
Pubchem ID :25250149

Safety of [ 287953-38-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 287953-38-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 18
Num. arom. heavy atoms 0
Fraction Csp3 0.91
Num. rotatable bonds 5
Num. H-bond acceptors 5.0
Num. H-bond donors 1.0
Molar Refractivity 73.17
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

84.09 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.13
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.77
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.64
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.12
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.32
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.87

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.72
Solubility 5.29 mg/ml ; 0.019 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.12
Solubility 2.13 mg/ml ; 0.00765 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.64
Solubility 6.44 mg/ml ; 0.0231 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.45 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.73

Application In Synthesis of [ 287953-38-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 287953-38-2 ]

[ 287953-38-2 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 124-63-0 ]
  • [ 73874-95-0 ]
  • [ 287953-38-2 ]
YieldReaction ConditionsOperation in experiment
91% at 20℃; for 16 h; Cooling with ice 5.00 g (25.0 mmol) of BOC-4-aminopiperidine are dissolved in pyridine (19.8 mL) and cooled in an ice bath. 2.13 mL (27.5 mmol) of methanesulfonyl chloride are added slowly. The reaction is stirred at RT for 16 h. After diluting with water, the reaction is extracted with DCM. Organic layers are washed with water, dried with MgS04 and filtered. The solvent is removed under reduced pressure to afford 6.30 g of (1 -Methanesulfonyl-piperidin-4-yl)-carbamic acid tert-butyl ester. Yield: 91 percent; ESI-MS: 279 [M+H]+
89% With triethylamine In dichloromethane at 20℃; for 1 h; EXAMPLE 4; Preparation of 4-(2-chloro-6-fluoro-benzoylamino)- 1 H-pyrazole-3 -carboxylic acid ( 1 -methanesulphonyl-piperidin-4-yl)-amide4A. 4-Amino-1H-pyrazole-3-carboxylic acid (l-methanesulphonyl-piperidin-4-yl) amideTo a stirred solution of 4-(N-BOC amino)piperidine (2.5 g, 12.5 mmoles) in dichloromethane (30 ml) was added triethylamine (2.1 ml, 15.0 mmoles), and then EPO <DP n="165"/>dropwise methanesulphonyl chloride (1.06 ml, 13.8 mmoles). The solution formed was stirred at room temperature for one hour. The reaction mixture was partitioned between EtOAc and water. The organic portion was washed with water, 2N HCl, brine, dried (MgSO4) filtered and evaporated in vacuo to give 4-(N-BOC-amino)-l- methanesulphonylpiperidine as a white solid (3.1g, 89percent).
55% With triethylamine In dichloromethane at 20℃; for 4 h; General procedure: To a stirred solution of 2 (0.20 g, 1.00 mmol) in anhydrous DCM(5 mL) was added Et3N (0.42 mL, 3.00 mmol) at room temperature.Then 3a–i (3.96 mmol) was added in small portions at room temperature.The reaction was stirred for 4 h at this temperature and then quenched the reaction with saturated aqueous solution ofNaHCO3. The aqueous layer was extracted with ethyl acetate(3 10 mL). The combined organic layers were dried over anhydrousNa2SO4, filtered, and concentrated. Silica gel flash columnchromatography (EtOAc/hexanes = 1:2) of the residue gave 4a–ias the product. Dissolved 4a–i (0.34 g, 0.97 mmol) in 25 mL TFAat room temperature, the reaction was stirred at room temperature for 10 h. Distilled the TFA under vacuum and then diluted with saturated aqueous solution of NaHCO3. The aqueous layer wasextracted with ethyl acetate (3 10 mL). The combined organiclayers were dried over anhydrous Na2SO4, filtered, and concentrated.Silica gel flash column chromatography (EtOAc/hexanes =1:1) of the residue gave 5a–i as the product.
References: [1] Patent: WO2014/184327, 2014, A1, . Location in patent: Page/Page column 27.
[2] Patent: WO2006/77414, 2006, A1, . Location in patent: Page/Page column 163-164.
[3] Bioorganic Chemistry, 2015, vol. 61, p. 21 - 27.
[4] Journal of Medicinal Chemistry, 2006, vol. 49, # 22, p. 6549 - 6560.
[5] Patent: US2006/14708, 2006, A1, . Location in patent: Page/Page column 13.
[6] Patent: EP2261213, 2010, A1, . Location in patent: Page/Page column 44-45.
  • 2
  • [ 87120-72-7 ]
  • [ 124-63-0 ]
  • [ 287953-38-2 ]
YieldReaction ConditionsOperation in experiment
91% With pyridine In pyridine at 20℃; for 16 h; Cooling with ice 5.00 g (25.0 mmol) of BOC-4-aminopiperidine are dissolved in pyridine (19.8 mL) and cooled in an ice bath. 2.13 mL (27.5 mmol) of methanesulfonyl chloride are added slowly.
The reaction is stirred at RT for 16 h.
After diluting with water, the reaction is extracted with DCM.
Organic layers are washed with water, dried with MgSO4 and filtered.
The solvent is removed under reduced pressure to afford 6.30 g of (1-Methanesulfonyl-piperidin-4-yl)-carbamic acid tert-butyl ester. Yield: 91percent; ESI-MS: 279 [M+H]+
References: [1] Patent: US8865744, 2014, B1, . Location in patent: Page/Page column 25; 26.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 287953-38-2 ]

Amides

Chemical Structure| 73874-95-0

A157670 [73874-95-0]

tert-Butyl piperidin-4-ylcarbamate

Similarity: 0.63

Chemical Structure| 287114-25-4

A153243 [287114-25-4]

tert-Butyl 8-azabicyclo[3.2.1]octan-3-ylcarbamate

Similarity: 0.62

Chemical Structure| 179110-74-8

A413223 [179110-74-8]

tert-Butyl piperidin-4-ylcarbamate hydrochloride

Similarity: 0.62

Chemical Structure| 147611-03-8

A134198 [147611-03-8]

tert-Butyl 7-azaspiro[3.5]nonan-2-ylcarbamate

Similarity: 0.61

Chemical Structure| 163271-08-7

A277159 [163271-08-7]

tert-Butyl (4-methylpiperidin-4-yl)carbamate

Similarity: 0.61

Amines

Chemical Structure| 70724-74-2

A121793 [70724-74-2]

N-Methyl-N-(piperidin-4-yl)methanesulfonamide

Similarity: 0.65

Chemical Structure| 402927-97-3

A116759 [402927-97-3]

4-Amino-1-(methylsulfonyl)piperidine

Similarity: 0.65

Chemical Structure| 651057-01-1

A121013 [651057-01-1]

1-(Methylsulfonyl)piperidin-4-amine hydrochloride

Similarity: 0.64

Chemical Structure| 73874-95-0

A157670 [73874-95-0]

tert-Butyl piperidin-4-ylcarbamate

Similarity: 0.63

Chemical Structure| 179110-74-8

A413223 [179110-74-8]

tert-Butyl piperidin-4-ylcarbamate hydrochloride

Similarity: 0.62

Sulfamides

Chemical Structure| 70724-74-2

A121793 [70724-74-2]

N-Methyl-N-(piperidin-4-yl)methanesulfonamide

Similarity: 0.65

Chemical Structure| 402927-97-3

A116759 [402927-97-3]

4-Amino-1-(methylsulfonyl)piperidine

Similarity: 0.65

Chemical Structure| 651057-01-1

A121013 [651057-01-1]

1-(Methylsulfonyl)piperidin-4-amine hydrochloride

Similarity: 0.64

Chemical Structure| 934107-80-9

A132273 [934107-80-9]

1-Methanesulfonylpiperidin-3-ylamine

Similarity: 0.60

Chemical Structure| 147751-16-4

A215124 [147751-16-4]

tert-Butyl methylsulfonylcarbamate

Similarity: 0.57

Related Parent Nucleus of
[ 287953-38-2 ]

Piperidines

Chemical Structure| 70724-74-2

A121793 [70724-74-2]

N-Methyl-N-(piperidin-4-yl)methanesulfonamide

Similarity: 0.65

Chemical Structure| 402927-97-3

A116759 [402927-97-3]

4-Amino-1-(methylsulfonyl)piperidine

Similarity: 0.65

Chemical Structure| 651057-01-1

A121013 [651057-01-1]

1-(Methylsulfonyl)piperidin-4-amine hydrochloride

Similarity: 0.64

Chemical Structure| 73874-95-0

A157670 [73874-95-0]

tert-Butyl piperidin-4-ylcarbamate

Similarity: 0.63

Chemical Structure| 179110-74-8

A413223 [179110-74-8]

tert-Butyl piperidin-4-ylcarbamate hydrochloride

Similarity: 0.62